Stream
Stories
-
Nektar posts results of Phase 2/3 NKTR-255 trial in relapsed/refractory large B-cell lymphoma
Results for the study were first posted on ClinicalTrials.gov on October 16, 2026. The terminated study enrolled 15 participants and had a primary completion date of May 22, 2024.
-
FDA approves Brytly, a nonprescription eye drop for eye redness
The FDA approved Brytly, apraclonidine ophthalmic solution 0.125%, for relief of eye redness due to minor irritations. The approval is the first nonprescription eye drop containing apraclonidine and is available to adults and children 12 years of age and older.
-
Actinium Pharmaceuticals names Sean Maenpaa senior vice president of business development
The appointment takes effect on October 12, 2026, and the new executive will lead partnering, licensing and strategic transactions across Actinium's targeted radiotherapy pipeline. He brings more than two decades of oncology business development experience, including senior roles at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical.
-
CHMP recommends marketing authorization for Kizfizo
The Committee for Medicinal Products for Human Use adopted a positive opinion on 15 October 2026, recommending a marketing authorization for Kizfizo, a 40 mg/ml oral suspension of temozolomide, for newly diagnosed glioblastoma multiforme in adults and for recurrent or progressing malignant glioma in adults and children from the age of one year. The applicant is Orphelia Pharma and the product is designated an orphan medicine.
-
CHMP adopts positive opinion on Yuviwel for achondroplasia
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorization for Yuviwel (navepegritide) for children 2 years and older with achondroplasia. The opinion notes that Yuviwel improves annualised growth velocity by 1.49 cm versus placebo in a 52-week trial.
-
CHMP recommends marketing authorization for Neuzafy
On 15 October 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Neuzafy, a filgrastim biosimilar. The applicant is CuraTeQ Biologics (Malta) Limited and Neuzafy will be available as 30 MU/0.5 ml and 48 MU/0.5 ml solutions for injection/infusion.
-
CHMP adopts positive opinion on Fovlussea
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending a marketing authorization for Fovlussea, a ranibizumab biosimilar for several retinal conditions. The applicant is Accord Healthcare S.L.U., and the product will be available as a 10 mg/ml solution for injection.
-
FDA announces support for forward compatibility of eCTD 4.0
The FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research announced support for forward compatibility of Electronic Common Technical Document (eCTD) Version 4.0. This notice informs stakeholders that submissions based on eCTD 4.0 are supported for forward compatibility.
-
$78 million for rural Texas health workforce and chronic disease prevention
The Trump Administration announced $78 million in Rural Health Transformation Program funding to 216 rural healthcare providers through the Rural Texas Strong initiative. The investment will support chronic disease prevention, workforce recruitment and retention, and upgrades to medical equipment and facilities across Texas.
-
MiniMed completes separation from Medtronic
MiniMed announced on Oct. 15, 2026 that it has completed its separation from Medtronic, becoming a fully independent company. Medtronic accepted 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 shares of MiniMed common stock, a 5.4x subscribed offer.
-
Pfizer registers Phase 3 trial of PF-08653944 in Chinese adults with overweight or obesity
The study plans to enroll an estimated 432 participants and compares berobenatide (PF-08653944) with placebo. It is scheduled to start on October 15, 2026, with primary completion expected on June 6, 2028.
-
Hinova registers Phase 3 trial of Deutenzalutamide in high-risk BCR prostate cancer
Hinova Pharmaceuticals Inc. has registered a Phase 3, randomized, double-blind, placebo-controlled study of Deutenzalutamide plus androgen deprivation therapy versus placebo plus ADT in patients with high-risk biochemical recurrence of prostate cancer. The study plans to enroll 1044 participants and is expected to start on October 31, 2026, with primary completion projected for December 31, 2029.